AORT vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The company exhibits a weak fundamental health with a Piotroski F-Score of just 2/9, indicating significant operational and financial concerns. Despite strong revenue growth of 18.4% and impressive recent earnings surprises, the negative profit margin (-2.16%) and negative ROE (-2.46%) reflect persistent profitability issues. Valuation metrics are stretched, with a Forward P/E of 50.97 and Price/Book of 4.65, while insider selling worth $9.73M signals management's lack of confidence. Although balance sheet liquidity is strong (Current Ratio: 3.93), the absence of Altman Z-Score and weak earnings quality undermine long-term sustainability.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
AORT vs MRK: Head-to-Head Comparison
This page compares Artivion, Inc. (AORT) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.